NASDAQ:KIN - Kindred Biosciences Stock Price, Forecast & News

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences Inc (NASDAQ:KIN) released its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Zacks' consensus estimate of ($0.37) by $0.02. The biopharmaceutical company earned $1.10 million during the quarter, compared to analyst estimates of $1.55 million. Kindred Biosciences had a negative net margin of 1,461.28% and a negative return on equity of 58.86%. View Kindred Biosciences' Earnings History.

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Kindred Biosciences.

8 analysts have issued 12 month price objectives for Kindred Biosciences' stock. Their forecasts range from $8.50 to $25.00. On average, they anticipate Kindred Biosciences' share price to reach $14.44 in the next year. This suggests a possible upside of 43.1% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

Press coverage about KIN stock has been trending negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kindred Biosciences earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Kindred Biosciences.

Kindred Biosciences saw a decline in short interest in February. As of February 14th, there was short interest totalling 647,300 shares, a decline of 14.0% from the January 30th total of 753,000 shares. Based on an average daily trading volume, of 127,700 shares, the short-interest ratio is currently 5.1 days. Approximately 1.8% of the company's shares are short sold. View Kindred Biosciences' Current Options Chain.

Some companies that are related to Kindred Biosciences include Arvinas (ARVN), Aimmune Therapeutics (AIMT), Akcea Therapeutics (AKCA), Zymeworks (ZYME), IGM Biosciences (IGMS), Alder Biopharmaceuticals (ALDR), Corcept Therapeutics (CORT), Constellation Pharmaceuticals (CNST), Endo International (ENDP), Amneal Pharmaceuticals (AMRX), TG Therapeutics (TGTX), Innoviva (INVA), Dicerna Pharmaceuticals (DRNA), ZEALAND PHARMA/S (ZEAL) and Nabriva Therapeutics (NBRV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO).

Kindred Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Ariel Investments LLC (4.56%), Renaissance Technologies LLC (3.02%), State Street Corp (1.79%), General American Investors Co. Inc. (1.32%), Geode Capital Management LLC (1.21%) and UBS Group AG (0.37%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

KIN stock was sold by a variety of institutional investors in the last quarter, including Ariel Investments LLC, Goldman Sachs Group Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Kindred Biosciences.

KIN stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, State Street Corp, Cambridge Investment Research Advisors Inc., Edgewood Management LLC, UBS Group AG, General American Investors Co. Inc., Prudential Financial Inc. and Barclays PLC. View Insider Buying and Selling for Kindred Biosciences.

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KIN stock can currently be purchased for approximately $10.09.

Kindred Biosciences has a market capitalization of $394.42 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.

The official website for Kindred Biosciences is http://kindredbio.com/.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]